NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis

BioMarin Pharmaceutical Inc. (BMRN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

BMRN

$66.53

+$0.10 (+0.15%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BMRN with… →

BMRN Key Statistics

As of Sep 4, 2026
Trading
Open
$65.79
Previous Close
$66.43
Day's Range
65.52–66.64
52-Week Range
49.26–70.98
Volume
2.30M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.24
Valuation
Market Cap
$12.88B
P/E Ratio
179.81
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.18
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.39
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.78
EPS (ttm)Profit attributable to each share over the last twelve months.
0.37
Financials (FY)
Revenue (FY)
$3.22B+12.87%
Net Income (FY)
$348.90M−18.26%
Profit marginThe share of revenue left as profit after all costs and taxes.
2.14%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
193.57M
1-Year Return
+17.23%
Dividend and dates
Earnings Date
October 26, 2026
Avg Volume
1.97M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BMRN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+11.95%
2025−9.58%
2024−31.83%
2023−6.83%
2022+17.14%
2021+0.75%
2020+3.71%
2019−0.70%
2018−4.51%
2017+7.64%
2016 (partial year)−16.34%

As of September 4, 2026.

BMRN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$3.22B$348.90M10.8%
2024$2.85B$426.86M15.0%
2023$2.42B$167.65M6.9%
2022$2.10B$141.56M6.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$3.22B$2.50B$409.50M$348.90M10.8%
2024$2.85B$2.27B$474.24M$426.86M15.0%
2023$2.42B$1.89B$185.78M$167.65M6.9%
2022$2.10B$1.59B$57.41M$141.56M6.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BMRN Valuation vs Biotechnology Median

Median of 656 stocks
MetricBMRNBiotechnology medianvs median
P/E179.8112.5714.3x the median
P/S ratio3.7815.260.2x the median
Profit margin2.14%0.00%2.1 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioMarin Pharmaceutical Inc. (BMRN) is capitalised at $12.88B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 3,221.

BMRN last closed at $66.53 on September 4, 2026. That is +$0.10 (+0.15%) against the previous close. Over the past 52 weeks the price has ranged from $49.26 to $70.98. The latest close sits 35.06% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $3.22B. Against the prior fiscal year total of $2.85B, that is a change of +12.87%. The same year closed with net income of $348.90M. That is −18.26% against the prior fiscal year. The reported profit margin is 2.14%. That is 2.1 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 0.37.

Across the 4 fiscal years on file, revenue moves from $2.10B in 2022 to $3.22B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 179.81 times earnings. That is 14.3 times the Biotechnology median of 12.57. On forward earnings the ratio is 10.18. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.39. Measured against sales, the shares trade at 3.78 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +17.23%. Measured over 10 years, that is −3.57% a year compounded. The reported beta is 0.24. Annualized volatility over the trailing 10 years is 35.06%.

Growth & Income

The record shows no dividend for BMRN.

2026 is still running; the price is +11.95% year to date. The strongest complete calendar year on file is 2022 at +17.14%; the weakest is 2024 at −31.83%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

BioMarin Pharmaceutical Inc. (BMRN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioMarin Pharmaceutical Inc. BMRN $12.88B 179.8
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. BioMarin Pharmaceutical Inc. trades at a P/E of 179.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Visit website →